Literature DB >> 28637661

The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment.

Shan Lin1, Roger T Luo2, Mahesh Shrestha1, Michael J Thirman2, James C Mulloy1.   

Abstract

Chromosome rearrangements involving the mixed-lineage leukemia gene (MLL) create MLL-fusion proteins, which could drive both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The lineage decision of MLL-fusion leukemia is influenced by the fusion partner and microenvironment. To investigate the interplay of fusion proteins and microenvironment in lineage choice, we transplanted human hematopoietic stem and progenitor cells (HSPCs) expressing MLL-AF9 or MLL-Af4 into immunodeficient NSGS mice, which strongly promote myeloid development. Cells expressing MLL-AF9 efficiently developed AML in NSGS mice. In contrast, MLL-Af4 cells, which were fully oncogenic under lymphoid conditions present in NSG mice, displayed compromised transformation capacity in a myeloid microenvironment. MLL-Af4 activated a self-renewal program in a lineage-dependent manner, showing the leukemogenic activity of MLL-Af4 was interlinked with lymphoid lineage commitment. The C-terminal homology domain (CHD) of Af4 was sufficient to confer this linkage. Although the MLL-CHD fusion protein failed to immortalize HSPCs in myeloid conditions in vitro, it could successfully induce ALL in NSG mice. Our data suggest that defective self-renewal ability and leukemogenesis of MLL-Af4 myeloid cells could contribute to the strong B-cell ALL association of MLL-AF4 leukemia observed in the clinic.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28637661      PMCID: PMC5561902          DOI: 10.1182/blood-2017-04-777185

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.

Authors:  Ahmad Rayes; Richard L McMasters; Maureen M O'Brien
Journal:  Pediatr Blood Cancer       Date:  2016-02-23       Impact factor: 3.167

2.  Lineage switch in childhood acute leukemia: an unusual event with poor outcome.

Authors:  Jorge G Rossi; Andrea R Bernasconi; Cristina N Alonso; Patricia L Rubio; Marta S Gallego; Carolina A Carrara; Myriam R Guitter; Silvia Eandi Eberle; Mariela Cocce; Pedro A Zubizarreta; María S Felice
Journal:  Am J Hematol       Date:  2012-06-08       Impact factor: 10.047

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription.

Authors:  Akihiko Yokoyama; Min Lin; Alpana Naresh; Issay Kitabayashi; Michael L Cleary
Journal:  Cancer Cell       Date:  2010-02-17       Impact factor: 31.743

5.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

6.  Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry.

Authors:  M R Baer; C C Stewart; D Lawrence; D C Arthur; K Mrózek; M P Strout; F R Davey; C A Schiffer; C D Bloomfield
Journal:  Leukemia       Date:  1998-03       Impact factor: 11.528

7.  Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.

Authors:  Kevin A Link; Shan Lin; Mahesh Shrestha; Melissa Bowman; Mark Wunderlich; Clara D Bloomfield; Gang Huang; James C Mulloy
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

8.  Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.

Authors:  Han Liu; Todd D Westergard; Amanda Cashen; David R Piwnica-Worms; Lori Kunkle; Ravi Vij; Can G Pham; John DiPersio; Emily H Cheng; James J Hsieh
Journal:  Cancer Cell       Date:  2014-04-14       Impact factor: 31.743

9.  The MLL recombinome of acute leukemias in 2013.

Authors:  C Meyer; J Hofmann; T Burmeister; D Gröger; T S Park; M Emerenciano; M Pombo de Oliveira; A Renneville; P Villarese; E Macintyre; H Cavé; E Clappier; K Mass-Malo; J Zuna; J Trka; E De Braekeleer; M De Braekeleer; S H Oh; G Tsaur; L Fechina; V H J van der Velden; J J M van Dongen; E Delabesse; R Binato; M L M Silva; A Kustanovich; O Aleinikova; M H Harris; T Lund-Aho; V Juvonen; O Heidenreich; J Vormoor; W W L Choi; M Jarosova; A Kolenova; C Bueno; P Menendez; S Wehner; C Eckert; P Talmant; S Tondeur; E Lippert; E Launay; C Henry; P Ballerini; H Lapillone; M B Callanan; J M Cayuela; C Herbaux; G Cazzaniga; P M Kakadiya; S Bohlander; M Ahlmann; J R Choi; P Gameiro; D S Lee; J Krauter; P Cornillet-Lefebvre; G Te Kronnie; B W Schäfer; S Kubetzko; C N Alonso; U zur Stadt; R Sutton; N C Venn; S Izraeli; L Trakhtenbrot; H O Madsen; P Archer; J Hancock; N Cerveira; M R Teixeira; L Lo Nigro; A Möricke; M Stanulla; M Schrappe; L Sedék; T Szczepański; C M Zwaan; E A Coenen; M M van den Heuvel-Eibrink; S Strehl; M Dworzak; R Panzer-Grümayer; T Dingermann; T Klingebiel; R Marschalek
Journal:  Leukemia       Date:  2013-04-30       Impact factor: 11.528

10.  Initiation of MLL-rearranged AML is dependent on C/EBPα.

Authors:  Ewa Ohlsson; Marie Sigurd Hasemann; Anton Willer; Felicia Kathrine Bratt Lauridsen; Nicolas Rapin; Johan Jendholm; Bo Torben Porse
Journal:  J Exp Med       Date:  2013-12-23       Impact factor: 14.307

View more
  10 in total

1.  Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia.

Authors:  Changya Chen; Wenbao Yu; Fatemeh Alikarami; Qi Qiu; Chia-Hui Chen; Jennifer Flournoy; Peng Gao; Yasin Uzun; Li Fang; James W Davenport; Yuxuan Hu; Qin Zhu; Kai Wang; Clara Libbrecht; Alex Felmeister; Isaiah Rozich; Yang-Yang Ding; Stephen P Hunger; Carolyn A Felix; Hao Wu; Patrick A Brown; Erin M Guest; David M Barrett; Kathrin M Bernt; Kai Tan
Journal:  Blood       Date:  2022-04-07       Impact factor: 22.113

2.  Defined Human Leukemic CD34+ Liquid Cultures to Study HDAC/Transcriptional Repressor Complexes.

Authors:  Roland Windisch; Sophie Kreissig; Christian Wichmann
Journal:  Methods Mol Biol       Date:  2023

Review 3.  Molecular processes involved in B cell acute lymphoblastic leukaemia.

Authors:  Camille Malouf; Katrin Ottersbach
Journal:  Cell Mol Life Sci       Date:  2017-08-17       Impact factor: 9.261

Review 4.  RNA Polymerase II-Dependent Transcription Initiated by Selectivity Factor 1: A Central Mechanism Used by MLL Fusion Proteins in Leukemic Transformation.

Authors:  Akihiko Yokoyama
Journal:  Front Genet       Date:  2019-01-14       Impact factor: 4.599

5.  The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): Revised characterisation of cytogenetic features.

Authors:  Denise Ragusa; Evgeny M Makarov; Oliver Britten; Daniela Moralli; Catherine M Green; Sabrina Tosi
Journal:  Cancer Rep (Hoboken)       Date:  2019-08-07

6.  Development of Mast Cell and Eosinophil Hyperplasia and HLH/MAS-Like Disease in NSG-SGM3 Mice Receiving Human CD34+ Hematopoietic Stem Cells or Patient-Derived Leukemia Xenografts.

Authors:  Laura J Janke; Denise M Imai; Heather Tillman; Rosalinda Doty; Mark J Hoenerhoff; Jiajie J Xu; Zachary T Freeman; Portia Allen; Natalie Wall Fowlkes; Ilaria Iacobucci; Kirsten Dickerson; Charles G Mullighan; Peter Vogel; Jerold E Rehg
Journal:  Vet Pathol       Date:  2020-11-19       Impact factor: 2.221

7.  Response of Myeloid Leukemia Cells to Luteolin is Modulated by Differentially Expressed Pituitary Tumor-Transforming Gene 1 (PTTG1) Oncoprotein.

Authors:  Pei-Yi Chen; Hsin-Jung Tien; Shih-Fen Chen; Chi-Ting Horng; Huei-Lin Tang; Hui-Ling Jung; Ming-Jiuan Wu; Jui-Hung Yen
Journal:  Int J Mol Sci       Date:  2018-04-12       Impact factor: 5.923

8.  Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis.

Authors:  Antonio Agraz-Doblas; Clara Bueno; Rachael Bashford-Rogers; Anindita Roy; Pauline Schneider; Michela Bardini; Paola Ballerini; Gianni Cazzaniga; Thaidy Moreno; Carlos Revilla; Marta Gut; Maria G Valsecchi; Irene Roberts; Rob Pieters; Paola De Lorenzo; Ignacio Varela; Pablo Menendez; Ronald W Stam
Journal:  Haematologica       Date:  2019-01-24       Impact factor: 9.941

Review 9.  MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)-Current Treatment Options. Is There a Role for CAR-T Cell Therapy?

Authors:  Oliver Britten; Denise Ragusa; Sabrina Tosi; Yasser Mostafa Kamel
Journal:  Cells       Date:  2019-10-29       Impact factor: 6.600

10.  Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia.

Authors:  Amit Kumar Jaiswal; Hellen Truong; Tiffany M Tran; Tasha L Lin; David Casero; Michael O Alberti; Dinesh S Rao
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.